Hikma Pharmaceuticals PLC ADR (HKMPY)
Company Info
Highlights
$6.52B
$1.70
34.58
2.41
$1.57B
$756.00M
$427.00M
$44.20 - $58.78
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Hikma Pharmaceuticals PLC ADR, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Hikma Pharmaceuticals PLC ADR had a return of 17.54% year-to-date (YTD) and 21.26% in the last 12 months. Over the past 10 years, Hikma Pharmaceuticals PLC ADR had an annualized return of -1.11%, while the S&P 500 had an annualized return of 11.29%, indicating that Hikma Pharmaceuticals PLC ADR did not perform as well as the benchmark.
HKMPY
17.54%
17.23%
5.80%
21.26%
6.99%
-1.11%
^GSPC (Benchmark)
4.22%
2.22%
9.51%
22.46%
12.74%
11.29%
Monthly Returns
The table below presents the monthly returns of HKMPY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 14.94% | 17.54% | |||||||||||
| 2024 | 7.85% | 1.16% | -2.71% | 0.42% | 3.08% | -2.72% | 2.31% | 10.05% | -6.73% | 0.81% | 1.28% | -1.24% | 13.16% |
| 2023 | 12.67% | -0.31% | 0.55% | 11.73% | -4.04% | 8.25% | 11.83% | 4.13% | -8.12% | -9.46% | -5.44% | 4.53% | 25.49% |
| 2022 | -7.24% | 0.25% | -1.59% | -12.86% | -9.47% | -8.24% | 7.17% | -26.65% | -0.38% | -5.52% | 25.38% | 3.54% | -36.37% |
| 2021 | -3.55% | -6.12% | 1.57% | 7.58% | 4.36% | -4.15% | 7.44% | -3.28% | -5.95% | 2.24% | -12.75% | 2.56% | -11.51% |
| 2020 | -2.98% | -1.31% | 1.36% | 14.50% | 10.02% | -13.70% | 1.50% | 14.61% | 5.64% | -1.26% | 5.15% | -0.85% | 33.47% |
| 2019 | -7.96% | 11.90% | 3.51% | -3.11% | -9.70% | 9.65% | 3.53% | 9.99% | 1.06% | 1.89% | -3.12% | 6.96% | 24.25% |
| 2018 | -7.89% | -13.67% | 42.80% | 1.53% | 4.29% | 11.01% | 1.08% | 26.08% | -1.47% | -8.57% | 1.14% | -4.99% | 47.25% |
| 2017 | 7.65% | 13.18% | -2.11% | -1.93% | -9.77% | -10.31% | -10.26% | -10.75% | -4.79% | -1.90% | -6.20% | 5.64% | -29.83% |
| 2016 | -19.60% | 3.13% | -0.88% | 13.44% | 3.99% | -5.82% | 9.23% | -12.20% | 0.00% | -22.87% | -8.13% | 4.01% | -35.45% |
| 2015 | 17.88% | 6.96% | -17.26% | 4.45% | -2.33% | -7.33% | 26.45% | -1.82% | -8.04% | -4.29% | 4.84% | 12.96% | |
| 2014 | 20.82% | 15.72% | -5.30% | 5.12% | 4.15% | 5.86% | -5.57% | -1.66% | 5.71% | 0.02% | 2.06% | 53.74% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 77, HKMPY is among the top 23% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Hikma Pharmaceuticals PLC ADR (HKMPY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Hikma Pharmaceuticals PLC ADR provided a 2.69% dividend yield over the last twelve months, with an annual payout of $1.58 per share. The company has been increasing its dividends for 13 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $1.58 | $1.58 | $1.24 | $1.10 | $1.04 | $0.92 | $0.80 | $0.70 | $0.66 | $0.64 | $0.64 | $0.48 |
Dividend yield | 2.69% | 3.16% | 2.72% | 2.95% | 1.73% | 1.33% | 1.52% | 1.62% | 2.21% | 1.48% | 0.94% | 0.79% |
Monthly Dividends
The table displays the monthly dividend distributions for Hikma Pharmaceuticals PLC ADR. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | $0.00 | ||||||||||
| 2024 | $0.00 | $0.00 | $0.94 | $0.00 | $0.00 | $0.00 | $0.00 | $0.64 | $0.00 | $0.00 | $0.00 | $0.00 | $1.58 |
| 2023 | $0.00 | $0.00 | $0.74 | $0.00 | $0.00 | $0.00 | $0.00 | $0.50 | $0.00 | $0.00 | $0.00 | $0.00 | $1.24 |
| 2022 | $0.00 | $0.00 | $0.72 | $0.00 | $0.00 | $0.00 | $0.00 | $0.38 | $0.00 | $0.00 | $0.00 | $0.00 | $1.10 |
| 2021 | $0.00 | $0.00 | $0.68 | $0.00 | $0.00 | $0.00 | $0.00 | $0.36 | $0.00 | $0.00 | $0.00 | $0.00 | $1.04 |
| 2020 | $0.00 | $0.00 | $0.60 | $0.00 | $0.00 | $0.00 | $0.00 | $0.32 | $0.00 | $0.00 | $0.00 | $0.00 | $0.92 |
| 2019 | $0.00 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.00 | $0.00 | $0.80 |
| 2018 | $0.00 | $0.00 | $0.00 | $0.46 | $0.00 | $0.00 | $0.00 | $0.24 | $0.00 | $0.00 | $0.00 | $0.00 | $0.70 |
| 2017 | $0.00 | $0.00 | $0.00 | $0.44 | $0.00 | $0.00 | $0.00 | $0.22 | $0.00 | $0.00 | $0.00 | $0.00 | $0.66 |
| 2016 | $0.00 | $0.00 | $0.00 | $0.42 | $0.00 | $0.00 | $0.00 | $0.00 | $0.22 | $0.00 | $0.00 | $0.00 | $0.64 |
| 2015 | $0.00 | $0.00 | $0.00 | $0.42 | $0.00 | $0.00 | $0.00 | $0.22 | $0.00 | $0.00 | $0.00 | $0.64 | |
| 2014 | $0.26 | $0.00 | $0.00 | $0.00 | $0.00 | $0.22 | $0.00 | $0.00 | $0.00 | $0.48 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Hikma Pharmaceuticals PLC ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Hikma Pharmaceuticals PLC ADR was 68.91%, occurring on Feb 28, 2018. Recovery took 192 trading sessions.
The current Hikma Pharmaceuticals PLC ADR drawdown is 13.70%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -68.91% | Feb 27, 2015 | 130 | Feb 28, 2018 | 192 | Jan 6, 2021 | 322 |
| -63.85% | Aug 5, 2021 | 270 | Sep 26, 2022 | — | — | — |
| -34.97% | Jun 10, 2011 | 12 | Sep 15, 2011 | 41 | Mar 1, 2013 | 53 |
| -16.74% | Jan 11, 2021 | 23 | Mar 5, 2021 | 42 | Jul 12, 2021 | 65 |
| -14.25% | Jul 25, 2014 | 11 | Sep 19, 2014 | 11 | Dec 8, 2014 | 22 |
Volatility
Volatility Chart
The current Hikma Pharmaceuticals PLC ADR volatility is 5.21%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Hikma Pharmaceuticals PLC ADR compared to its peers in the Drug Manufacturers - Specialty & Generic industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for HKMPY in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, HKMPY has a PE value of 34.6. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for HKMPY in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, HKMPY has a PEG value of 2.4. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Hikma Pharmaceuticals PLC ADR.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |